## (19) World Intellectual Property Organization International Bureau



# 

#### (43) International Publication Date 7 April 2005 (07.04.2005)

### PCT

## (10) International Publication Number WO 2005/031303 A2

(51) International Patent Classification7:

G01N

(21) International Application Number:

PCT/US2004/030987

(22) International Filing Date:

21 September 2004 (21.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data: 60/504,796

22 September 2003 (22.09.2003)

- (71) Applicant (for all designated States except US): UNI-VERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; 308 Bynum Hall, Campus Box 4105, Chapel Hill, North Carolina 27599-4105 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LENTZ, Barry, R. [US/US]; 179 Tradescant Drive, Chapel Hill, North Car-

Chapel Hill, North Carolina 27514 (US). HUANG, Jin-Ming [CN/US]; 2200 Allen Easley Street, Apt. 5H, Winston Salem, North Carolina 27106 (US).

- (74) Agent: MYERS BIGEL SIBLEY & SAJOVEC, P.A.; P.O. Box 37428, Raleigh, North Carolina 27627 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,



methods of the invention can be used to carry out any clotting assay or other assay of clotting activity that traditionally relies on platelet membranes or synthetic membrane preparation by substituting therefor the soluble phospholipids of the invention. Assay compositions and kits comprising the soluble phospholipids of the invention are also provided.